RTW Investments

40 10TH Avenue
New York, NY 10014

Website: rtwfunds.com

Firm Size

• Assets Under Management (AUM):$8.4 Billion
• Number of Funds:3
• Employees:59
• Firm Type:

Description

RTW Investments LP in New York, NY is an investment firm that specializes in global healthcare investments. The firm focuses on making long-term investments in innovative companies within the healthcare sector, including pharmaceuticals, medical devices, diagnostics, and biotechnology. RTW Investments LP takes a research-driven approach to investing and seeks out opportunities in companies that are at various stages of development, from early-stage startups to established industry leaders. The firm looks for companies with promising products or technologies that have the potential to disrupt the healthcare industry and improve patient outcomes. The investment team at RTW Investments LP includes experienced professionals with backgrounds in healthcare research, finance, and operations. They leverage their expertise and network to identify investment opportunities and actively support portfolio companies. With a global perspective, RTW Investments LP invests in companies located worldwide, including the United States, Europe, and Asia. The firm aims to generate attractive risk-adjusted returns for its investors while contributing to advancements in the healthcare sector. In summary, RTW Investments LP is a New York-based investment firm that specializes in global healthcare investments. The firm takes a research-driven approach and seeks out innovative companies within the healthcare sector. Their experienced team identifies investment opportunities worldwide and actively supports portfolio companies to drive growth and improve patient outcomes.

Latest News

Powered by

Mar 18, 2024: Spyre Therapeutics Announces $180 Million Private Placement
Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including Adage Capital Partners LP, Avidity Partners, Boxer Capital, Darwin Global Management, Deep Track Capital, funds affiliated with Farallon Capital Management, L.L.C., Logos Capital, Perceptive Advisors, RTW Investments, a leading biotechnology investor associated with one of the largest alternative asset managers, and a large investment management firm.

Feb 29, 2024: Avidity Biosciences Announces Oversubscribed $400 Million Private Placement


Aug 03, 2023: Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases, today announced the close of an oversubscribed $60 million Series B financing round extension, bringing the total Series B financing round to $145 million . New investors, Bain Capital Life Sciences and GordonMD® Global Investments LP, join existing investors Gilead Sciences, Westlake Village BioPartners, Vida Ventures, Northpond Ventures, RTW Investments, Insight Partners, CAM Capital, LYFE Capital, jVen Capital, and others.

Apr 12, 2023: RTW Investments, LP Issues Statement Regarding Cutera's Special Meeting of Stockholders
 RTW Investments, LP ("RTW"), which manages funds holding approximately 9.3% of the outstanding shares of Cutera, Inc. (the "Company") (Nasdaq: CUTR), today announced that it was in favor of the Company holding the previously-called Special Meeting of Stockholders (the "Special Meeting") for the purpose of reconstituting the Board of Directors (the "Board") of the Company. RTW is concerned about the events that have transpired at the Company this past week, particularly with respect to the Board's removal of David Mowry as the Chief Executive Officer ("CEO") of the Company on April 11, 2023 .